Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 0.533 | uM | 7537.091 | 0.7711 | 0.7588 | 2.0227 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 2.67 | uM | 7537.091 | 0.7369 | 0.7198 | 2.0227 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 13.3 | uM | 7537.091 | 0.6222 | 0.5818 | 2.0227 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 66.7 | uM | 7537.091 | 0.4952 | 0.4130 | 2.0227 | |
| SUM52PE | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.0000853 | uM | 7539.092 | 1.0173 | 1.0283 | 1.2233 | |
| SUM52PE | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000427 | uM | 7539.092 | 1.0044 | 1.0073 | 1.2233 | |
| SUM52PE | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.00213 | uM | 7539.092 | 0.9505 | 0.9187 | 1.2233 | |
| SUM52PE | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.0107 | uM | 7539.092 | 0.9877 | 0.9798 | 1.2233 | |
| SUM52PE | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.0533 | uM | 7539.092 | 0.9475 | 0.9137 | 1.2233 | |
| SUM52PE | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.267 | uM | 7539.092 | 0.9899 | 0.9835 | 1.2233 | |
| SUM52PE | HR+ | Luminal | Erlotinib | EGFR | ErbB | 1.33 | uM | 7539.092 | 1.0255 | 1.0416 | 1.2233 | |
| SUM52PE | HR+ | Luminal | Erlotinib | EGFR | ErbB | 6.67 | uM | 7539.092 | 0.9581 | 0.9312 | 1.2233 | |
| SUM52PE | HR+ | Luminal | Erlotinib | EGFR | ErbB | 33.3 | uM | 7539.092 | 0.4670 | 0.0733 | 1.2233 | |
| SUM52PE | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000171 | uM | 7540.09 | 0.9058 | 0.6813 | 0.5702 | |
| SUM52PE | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7540.09 | 1.0321 | 1.1138 | 0.5702 | |
| SUM52PE | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7540.09 | 1.0063 | 1.0222 | 0.5702 | |
| SUM52PE | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7540.09 | 0.8051 | 0.3674 | 0.5702 | |
| SUM52PE | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.107 | uM | 7540.09 | 1.0195 | 1.0690 | 0.5702 | |
| SUM52PE | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.533 | uM | 7540.09 | 0.8586 | 0.5307 | 0.5702 | |
| SUM52PE | HR+ | Luminal | Erlotinib | EGFR | ErbB | 2.67 | uM | 7540.09 | 1.0313 | 1.1110 | 0.5702 | |
| SUM52PE | HR+ | Luminal | Erlotinib | EGFR | ErbB | 13.3 | uM | 7540.09 | 0.6924 | 0.0497 | 0.5702 | |
| SUM52PE | HR+ | Luminal | Erlotinib | EGFR | ErbB | 66.7 | uM | 7540.09 | 0.6615 | -0.0311 | 0.5702 | |
| SUM52PE | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000171 | uM | 7541.091 | 1.0436 | 1.0614 | 1.4119 | |
| SUM52PE | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7541.091 | 0.9227 | 0.8892 | 1.4119 | |
| SUM52PE | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7541.091 | 1.0493 | 1.0694 | 1.4119 |